The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
In this video, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL, discusses the results of the iMMunoPET study (NCT04814615), a Phase II trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (MM). This tracer demonstrated the ability to detect evidence of disease in patients in whom standard FDG PET/CT was negative, as well as to provide more accurate identification of myeloma sites. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
